REMARKS

Claims 1-8 are currently pending in this application. Claims 5-8 have been canceled as there has been duplicate numbering of claim 5. New claims 9-11 are actually originally misnumbered claims 5-8. Thus, no new matter has been added as a result of this amendment.

In the response to the Office Action dated August 5, 2002, applicants elect the cytokine IL-4 in claim 6 for prosecution at this time, with traverse.

In summary, claim 1 as filed requires that the pluripotential cells are contacted with a factor which causes the cells to mature and express characteristics of dendritic cells. Claims 2 - 4 read on claim 1. Claims 5 and 6 are limited to GMCSF being that factor. Claim 6 reads on claim 5 and will now be further limited to IL-4 as the cytokine and GMCSF as the factor for purposes of examination. New claim 9 depends from and read on claim 6, i.e., requiring GMCSF and IL-4. New claims 10 and 11 read on claim 1, i.e., requiring a factor.

A one-month extension of time up to and including Saturday, October 5, 2002 accompanies this amendment. Please charge the requisite fee for small entity of $55.00 to our deposit account number 08-0219.

Respectfully submitted,



Ann-Louise Kerner, Ph.D.
Attorney for Applicant
Reg. No. 33,523

Dated: October 7, 2002

Hale and Dorr LLP
60 State Street
Boston, MA 02109
617-526-6000 (telephone)
617-526-5000 (facsimile)

EXHIBIT A

Marked-Up Version of Pending Claims

1. An *in vitro* method for producing dendritic cells from pluripotential cells, comprising contacting the pluripotential cells with a factor for a time sufficient for the pluripotential cells to mature and express characteristics of dendritic cells.

2. The method of claim 1, wherein the pluripotential cells are CD14 positive mononuclear pluripotential cells.

3. The method of claim 1, wherein the pluripotential cells are peripheral blood mononuclear cells.

4. The method of claim 1, wherein the pluripotential cells are monocytes.

5. The method of claim 1, wherein the factor comprises GM-CSF.

6. The method of claim 5, wherein the factor further comprises a cytokine selected from the group consisting of IL-4; IL-13; IL-4 and IL-1β; IL-13 and IL-1β; IL-4 and TNF-α; IL-13 and TNF-α; IL-4, IL-1β, and TNF-α; IL-13, IL-1β, and TNF-α; IL-4 and IL-12; IL-13 and IL-12; IL-4 and stem cell factor, IL-13 and stem cell factor; IL-4 and IL-15; and IL-13 and IL-15.

~~5. The method of claim 5, wherein the GM-CSF is present at a concentration of between about 200 U/ml to about 2000 U/ml.~~

~~7. The method of claim 1, wherein the dendritic cells express high levels of MHC class molecules.~~

~~8. The method of claim 1, wherein the dendritic cells have the capacity to stimulating resting T cells.~~

9. (new) The method of claim 6, wherein the GM-CSF is present at a concentration of between about 200 U/ml to about 2000 U/ml.

10. (new) The method of claim 1, wherein the dendritic cells express high levels of MHC class molecules.

11. (new) The method of claim 1, wherein the dendritic cells have the capacity to stimulating resting T cells.